

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-13 (Cancelled).

14 (Currently amended). An isolated androgen receptor transcriptional coregulatory protein which interacts with androgen receptor to regulate androgen-dependent gene expression, comprising:

(a) ~~an the amino acid sequence selected from the group consisting of SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, and SEQ ID NO:10;~~

(b) an amino acid sequence having at least 85% sequence identity to (a) and the activity of (a); or

(c) a fragment of (a) or (b) and having the activity of (a).

15 (Original). The protein of claim 14, which comprises the amino acid sequence of SEQ ID NO:4.

Claims 16-18 (Cancelled).

19 (Original). The protein of claim 14, which comprises an amino acid sequence having at least 85% sequence identity to (a) and the activity of (a).

20(Original). The protein of claim 14, which comprises a fragment of (a) or (b) and having the activity of (a).

Claims 21-26 (Cancelled).

27(Currently amended). A molecule ~~having the~~ which comprises the antigen-binding portion of an antibody ~~capable of binding to~~ specific for the protein of claim 14.

28(Original). The molecule of claim 27, which is a monoclonal antibody.

Claims 29 and 30 (Cancelled).

31(Currently amended). A method of screening for and identifying inhibitors that disrupt the interaction between androgen receptor and androgen receptor transcriptional coregulatory protein, comprising:

providing an assay system for detecting and quantitating androgen receptor and androgen receptor transcriptional coregulatory protein interaction based on the level of activity of a reporter gene product produced upon interaction of the androgen receptor and the androgen receptor transcriptional coregulatory protein;

incubating androgen receptor and an androgen receptor transcriptional coregulatory protein with or without a potential inhibitor that disrupts the interaction between the androgen

Appln. No. 09/816,669
Amd. dated December 3, 2003
Reply to Office Action of October 7, 2003

receptor and the androgen receptor transcriptional coregulatory protein, wherein the androgen receptor transcriptional coregulatory protein comprises an the amino acid ~~selected from the group consisting of SEQ ID NO:2, sequence of SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, and SEQ ID NO:14;~~

determining the level of activity of a reporter gene product in the presence of the potential inhibitor relative to the level of activity of the reporter gene product in the absence of the potential inhibitor;

identifying as an inhibitor any potential inhibitor for which said determining step determines that the level of activity of the reporter gene product in the presence of the potential inhibitor is substantially less than that in the absence of the potential inhibitor.

32(Original). The method of claim 31, further comprising the step of isolating the inhibitor identified in said identifying step.

Claims 33 and 34 (Cancelled).